ABTI Alpha-Beta Technology Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABTI Alpha-Beta Technology

ABTI 0.200

+99,900.0%

Jun 17 12:34 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rosemary who wrote (55)	5/4/1997 9:55:00 AM
From: Rosemary	of 572

In February 1997, the Company completed patient enrollment into its Phase III trial of Betafectin for the prevention of post-surgical infection among patients undergoing gastrointestinal surgery. The Company is currently in the process of collecting and verifying the clinical data. The statistical analysis of the clinical data will begin once all of the data has been collected and verified. The Company expects to unblind and announce the results of the Phase III trial at the end of the second quarter of 1997, following the analysis of the data. This information was taken from ABTI's last quarter report.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next